Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;7(6):2621-2628.
doi: 10.1002/cam4.1510. Epub 2018 May 9.

Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients

Jasmine Chauzeix  1   2 , Marie-Pierre Laforêt  1 , Mélanie Deveza  1 , Liam Crowther  2 , Elodie Marcellaud  2 , Paco Derouault  3 , Anne-Sophie Lia  3 , François Boyer  2 , Nicolas Bargues  1 , Guillaume Olombel  2   4 , Arnaud Jaccard  2   5 , Jean Feuillard  1   2 , Nathalie Gachard  1   2 , David Rizzo  1   2
Affiliations

Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients

Jasmine Chauzeix et al. Cancer Med. 2018 Jun.

Abstract

More than 35 years after the Binet classification, there is still a need for simple prognostic markers in chronic lymphocytic leukemia (CLL). Here, we studied the treatment-free survival (TFS) impact of normal serum protein electrophoresis (SPE) at diagnosis. One hundred twelve patients with CLL were analyzed. The main prognostic factors (Binet stage; lymphocytosis; IGHV mutation status; TP53, SF3B1, NOTCH1, and BIRC3 mutations; and cytogenetic abnormalities) were studied. The frequencies of IGHV mutation status, cytogenetic abnormalities, and TP53, SF3B1, NOTCH1, and BIRC3 mutations were not significantly different between normal and abnormal SPE. Normal SPE was associated with Binet stage A, nonprogressive disease for 6 months, lymphocytosis below 30 G/L, and the absence of the IGHV3-21 gene rearrangement which is associated with poor prognosis. The TFS of patients with normal SPE was significantly longer than that of patients with abnormal SPE (log-rank test: P = 0.0015, with 51% untreated patients at 5.6 years and a perfect plateau afterward vs. a median TFS at 2.64 years for abnormal SPE with no plateau). Multivariate analysis using two different Cox models and bootstrapping showed that normal SPE was an independent good prognostic marker for either Binet stage, lymphocytosis, or IGHV mutation status. TFS was further increased when both normal SPE and mutated IGHV were present (log-rank test: P = 0.008, median not reached, plateau at 5.6 years and 66% untreated patients). A comparison with other prognostic markers suggested that normal SPE could reflect slowly advancing CLL disease. Altogether, our results show that a combination of normal SPE and mutated IGHV genes defines a subgroup of patients with CLL who evolve very slowly and who might never need treatment.

Keywords: IGHV; Chronic lymphocytic leukemia; prognosis; serum protein electrophoresis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meyer curves for treatment‐free survival according to SPE status.
Figure 2
Figure 2
Kaplan–Meyer curves for treatment‐free survival according to SPE and IGHV mutation status.
See this image and copyright information in PMC

References

    1. Swerdlow, S. H. , and International Agency for Research on Cancer . 2008. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon.
    1. Tamaru, J.‐I. 2017. 2016 revision of the WHO classification of lymphoid neoplasms. Rinsho Ketsueki 58:2188–2193. - PubMed
    1. Matutes, E. , Owusu‐Ankomah K., Morilla R., Garcia Marco J., Houlihan A., Que T. H., et al. 1994. The immunological profile of B‐cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8:1640–1645. - PubMed
    1. Moreau, E. J. , Matutes E., A'hern R. P., Morilla A. M., Morilla R. M., Owusu‐Ankomah K. A., et al. 1997. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am. J. Clin. Pathol. 108:378–382. - PubMed
    1. Binet, J. L. , Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., et al. 1981. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198–206. - PubMed

Publication types